8 Analysts Have This To Say About Integra Lifesciences
8 Analysts Have This To Say About Integra Lifesciences
8位分析师就英特格拉生命科学发表看法
In the last three months, 8 analysts have published ratings on Integra Lifesciences (NASDAQ:IART), offering a diverse range of perspectives from bullish to bearish.
在过去的三个月中，有8位分析师公布了对Integra Lifesciences（纳斯达克股票代码：IART）的评级，提供了从看涨到看跌的不同视角。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的收视率，展示了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.12, a high estimate of $40.00, and a low estimate of $24.00. A decline of 21.34% from the prior average price target is evident in the current average.
分析师评估的12个月目标股价揭示了进一步的见解，平均目标价为28.12美元，最高估计为40.00美元，低估值为24.00美元。目前的平均价格比先前的平均目标股价下降了21.34％。
Diving into Analyst Ratings: An In-Depth Exploration
深入分析师评级：深度探索
An in-depth...
对分析...
登录免费看全文
登录/注册